The Enterprise Value as of September 2024 (TTM) for Prometheus Biosciences, Inc. (RXDX) is 9.47B

According to Prometheus Biosciences, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 9.47B. This represents a change of 194.22% compared to the average of 3.22B of the last 4 quarters.

Prometheus Biosciences, Inc. (RXDX) Historical Enterprise Value (quarterly & annually)

How has RXDX Enterprise Value performed in the past?

The mean historical Enterprise Value of Prometheus Biosciences, Inc. over the last ten years is 1.27B. The current 9.47B Enterprise Value has changed 74.44% with respect to the historical average. Over the past ten years (40 quarters), RXDX's Enterprise Value was at its highest in in the March 2023 quarter at 5.01B. The Enterprise Value was at its lowest in in the March 2021 quarter at -151597832.08.

Prometheus Biosciences, Inc. (RXDX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Prometheus Biosciences, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Prometheus Biosciences, Inc. (RXDX) Average Enterprise Value

How has RXDX Enterprise Value performed in the past?

The current Enterprise Value of Prometheus Biosciences, Inc. (RXDX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Prometheus Biosciences, Inc. (RXDX) Enterprise Value vs. Peers

How is RXDX’s Enterprise Value compared to its peers?

Prometheus Biosciences, Inc.’s Enterprise Value is greater than Apellis Pharmaceuticals, Inc. (5.11B), greater than Akero Therapeutics, Inc. (1.56B), greater than Immunovant, Inc. (4.42B), greater than Madrigal Pharmaceuticals, Inc. (4.91B), greater than Roivant Sciences Ltd. (3.79B), greater than Krystal Biotech, Inc. (4.95B), greater than 89bio, Inc. (712.19M), greater than Pliant Therapeutics, Inc. (762.35M), greater than Arcellx, Inc. (3.80B), greater than Stoke Therapeutics, Inc. (586.20M), greater than Viking Therapeutics, Inc. (5.95B), greater than Intercept Pharmaceuticals, Inc. (915.81M), greater than Terns Pharmaceuticals, Inc. (458.36M), greater than Reata Pharmaceuticals, Inc. (6.68B), greater than IVERIC bio, Inc. (5.14B), greater than Blueprint Medicines Corporation (6.16B), greater than Amylyx Pharmaceuticals, Inc. (89.50M), less than Karuna Therapeutics, Inc. (12.43B), greater than Day One Biopharmaceuticals, Inc. (1.01B),

Build a custom stock screener for Prometheus Biosciences, Inc. (RXDX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Prometheus Biosciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Prometheus Biosciences, Inc. (RXDX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Prometheus Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.